Clinigen announces key executive appointments to drive the next phase of growth and deliver increased investor value
London, 1 May 2025 – Clinigen, the global specialist pharmaceutical services group, today announced the appointment of Nihad Hasagic as Senior Vice President for Clinigen Lifecycle Services (SVP CLS). Reporting to the Chief Executive Officer (CEO), this appointment emphasises Clinigen’s commitment to accelerating growth, enhancing its market position, and driving long-term value for clients and investors, ultimately contributing to improved patient outcomes.
CLS plays a key role in Clinigen’s growing service portfolio, helping to facilitate accelerated pathways to patients for critical medicines at every stage of their lifecycle, even in complex markets. Uniquely positioned within a global biotechnology and pharmaceutical services outsourcing market predicted to grow at a CAGR of 6.7% and reach USD 1.21 billion by 2034[1], CLS will unlock significant growth opportunities by offering new standalone services in Pharmacovigilance, Regulatory Affairs, and Medical Information to pharmaceutical and biopharmaceutical clients globally. The scalable nature of CLS's service delivery model allows for efficient expansion to meet this increasing demand.
This key appointment is part of a broader leadership realignment designed to sharpen the company's focus on achieving its growth objectives and capitalise on key market opportunities. To further bolster its growth agenda, Keith Byrne, Group Head of Corporate Development, will now report directly to the CEO. A qualified chartered accountant with over 20 years of corporate experience primarily in the healthcare and pharma services industry and significant expertise in corporate development, Keith’s closer alignment with the CEO will further accelerate the company's corporate development growth plans.
Previously, as SVP of Strategic Initiatives, Nihad was pivotal in successful acquisitions and the development of the company's core growth strategy, including his foundational work in launching CLS and shaping its commercial strategy. This track record, combined with over 20 years of experience in the healthcare, life science, and specialty chemicals industries, leading multiple acquisitions and corporate initiatives, makes him exceptionally well-suited to lead the new division and capture the opportunities in the rapidly expanding specialist pharma services market. His deep market understanding, and proven ability to drive important growth will be critical to establishing CLS as a significant value driver and market differentiator.
Jerome Charton, CEO of Clinigen says, “There is no one better placed than Nihad to lead Clinigen Lifecycle Services as we continue to strengthen our market presence, capture high-growth specialist pharma services opportunities, and drive enhanced returns for our investors. The direct reporting line for Keith in Corporate Development will also be instrumental in accelerating our expansion. CLS plays a vital role in strengthening the safety and accessibility of new medicines for patients, and under Nihad’s leadership, we are confident in its ability to deliver significant value to our clients and, most importantly, contribute to positive outcomes for the patients they serve.”
Nihad Hasagic, Senior Vice President of Clinigen Lifecycle Services, said: “I’m excited to focus on accelerating the growth of CLS by strengthening our industry position and ensuring we continue to deliver value to our clients and stakeholders. With the foundation we've already built, we can better support the transition of innovative medicines and have a positive impact on patients' lives.”
Keith Byrne, Group Head Corporate Development of Clinigen commented: “This closer alignment demonstrates the importance of corporate development in supporting Clinigen’s ambitious growth trajectory. I look forward to leveraging my network and expertise to strengthen our M&A pipeline to deliver acquisitions in line with our strategy, that support both our competitive positioning and growth ambitions.”
This strategic leadership change positions Clinigen for continued growth and the delivery of enhanced value to its clients, partners, and shareholders in the growing and evolving specialist pharmaceutical services landscape. The changes will be effective from today.
For media enquiries, please contact:
Email: clinigen@fightorflight.com
Notes for Editors:
About Clinigen
Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa, and the Asia Pacific. Clinigen has more than 1,100 employees across five continents in 15 countries and provides access in more than 130 countries every year.
For more information on Clinigen, please visit www.clinigen.com.
[1] https://www.biospace.com/press-releases/biotechnology-and-pharmaceutical-services-outsourcing-market-size-share-trends-analysis-report-by-2034